Tenax Therapeutics, INC Form 4 insider transactions
NASDAQ
June Sherie Almenoff, a director at Tenax Therapeutics, acquired 100,000 stock options on December 10, 2024.
NASDAQ
Director Gerald T. Proehl acquired common stock and warrants of Tenax Therapeutics through a private placement, according to a Form 4 filing.
NASDAQ
Form 4: Tenax Therapeutics Director Michael H. Davidson Acquires Shares and Warrants in Private Placement
Director Michael H. Davidson purchased shares, pre-funded warrants, and warrants of Tenax Therapeutics in a private placement on August 8, 2024.
NASDAQ
Chief Medical Officer of Tenax Therapeutics, Stuart Rich, reports the acquisition of stock options and adjustments to previously reported holdings due to stock splits.
NASDAQ
CEO Christopher Giordano reports the acquisition of stock options in Tenax Therapeutics, Inc.